Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY21 results · Apr–Jun 2020
Marksans Pharma reported revenue from operations of ₹331.15 crore (up 35.1% from Q1 FY20) and net profit of ₹49.37 crore (up 119.6% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 331.15 | 245.03 | +35.1% | 335.35 | −1.3% |
| Other income | 0.18 | 2.18 | −91.6% | 0.03 | +600.0% |
| Total income | 331.33 | 247.21 | +34.0% | 335.38 | −1.2% |
| Profit before tax | 61.40 | 27.61 | +122.4% | 57.56 | +6.7% |
| Net profit for the period | 49.37 | 22.48 | +119.6% | 42.74 | +15.5% |
| EPS, basic (₹) | 1.20 | 0.52 | +130.8% | 1.00 | +20.0% |
| Net margin (%) | 14.9 | 9.2 | 12.7 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.96 | 92.42 | +68.8% | 113.64 | +37.2% |
| Other income | 0.05 | 2.15 | −97.7% | (0.08) | Turned profit |
| Total income | 156.01 | 94.57 | +65.0% | 113.55 | +37.4% |
| Profit before tax | 24.92 | 7.91 | +215.1% | 13.17 | +89.2% |
| Net profit for the period | 22.06 | 5.66 | +290.0% | 7.41 | +197.6% |
| EPS, basic (₹) | 0.54 | 0.14 | +285.7% | 0.18 | +200.0% |
| Net margin (%) | 14.1 | 6.1 | 6.5 |
Consolidated
- Filed with BSE
- 08 Aug 2020, 14:14 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2020, 14:14 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE